Journal of Biological Chemistry · 2009 · 57 citations · 25 references
Life SciencesCell BiologyGeneticsApoptosisCell SignalingSignal TransductionApoptosis ModulationApoptosis RegulationApoptotic Signal TransductionApoptotic SignalingDeath ReceptorsApoptosis InductionApoptotic Cell Death RegulationProtein-protein Interactions In Apoptosis
Proapoptotic receptor agonists cause cellular demise through the activation of the extrinsic and intrinsic apoptotic pathways. Inhibitor of apoptosis (IAP) proteins block apoptosis induced by diverse stimuli. Here, we demonstrate that IAP antagonists in combination with Fas ligand (FasL) or the death receptor 5 (DR5) agonist antibody synergistically stimulate death in cancer cells and inhibit tumor growth. Single-agent activity of IAP antagonists relies on tumor necrosis factor-α signaling. By contrast, blockade of tumor necrosis factor-α does not affect the synergistic activity of IAP antagonists with FasL or DR5 agonist antibody. In most cancer cells, proapoptotic receptor agonist-induced cell death depends on amplifying the apoptotic signal via caspase-8-mediated activation of Bid and subsequent activation of the caspase-9-dependent mitochondrial apoptotic pathway. In the investigated cancer cell lines, induction of apoptosis by FasL or DR5 agonist antibody can be inhibited by knockdown of Bid. However, knockdown of X chromosome-linked IAP (XIAP) or antagonism of XIAP allows FasL or DR5 agonist antibody to induce activation of effector caspases efficiently without the need for mitochondrial amplification of the apoptotic signal and thus rescues the effect of Bid knockdown in these cells. Proapoptotic receptor agonists cause cellular demise through the activation of the extrinsic and intrinsic apoptotic pathways. Inhibitor of apoptosis (IAP) proteins block apoptosis induced by diverse stimuli. Here, we demonstrate that IAP antagonists in combination with Fas ligand (FasL) or the death receptor 5 (DR5) agonist antibody synergistically stimulate death in cancer cells and inhibit tumor growth. Single-agent activity of IAP antagonists relies on tumor necrosis factor-α signaling. By contrast, blockade of tumor necrosis factor-α does not affect the synergistic activity of IAP antagonists with FasL or DR5 agonist antibody. In most cancer cells, proapoptotic receptor agonist-induced cell death depends on amplifying the apoptotic signal via caspase-8-mediated activation of Bid and subsequent activation of the caspase-9-dependent mitochondrial apoptotic pathway. In the investigated cancer cell lines, induction of apoptosis by FasL or DR5 agonist antibody can be inhibited by knockdown of Bid. However, knockdown of X chromosome-linked IAP (XIAP) or antagonism of XIAP allows FasL or DR5 agonist antibody to induce activation of effector caspases efficiently without the need for mitochondrial amplification of the apoptotic signal and thus rescues the effect of Bid knockdown in these cells. IntroductionApoptosis, or programmed cell death, is a genetically regulated process with critical roles in development and homeostasis in metazoans (1.Steller H. Science. 1995; 267: 1445-1449Crossref PubMed Scopus (2423) Google Scholar). Deficient apoptosis leads to the absence of normal cell death and contributes to the development and progression of human cancers (2.Fesik S.W. Nat. Rev. Cancer. 2005; 5: 876-885Crossref PubMed Scopus (926) Google Scholar). Apoptotic cell death can be initiated through the engagement of cell surface proapoptotic receptors by their specific ligands or by changes in internal cellular integrity (3.Ashkenazi A. Dixit V.M. Science. 1998; 281: 1305-1308Crossref PubMed Scopus (5114) Google Scholar, 4.Kaufmann S.H. Vaux D.L. Oncogene. 2003; 22: 7414-7430Crossref PubMed Scopus (254) Google Scholar). Both of these pathways converge at the activation of caspases, cysteine-dependent aspartyl-specific proteases that comprise the effector arm of apoptotic cell death (5.Salvesen G.S. Abrams J.M. Oncogene. 2004; 23: 2774-2784Crossref PubMed Scopus (212) Google Scholar, 6.Shi Y. Protein Sci. 2004; 13: 1979-1987Crossref PubMed Scopus (244) Google Scholar). The intrinsic or mitochondrial pathway is initiated by developmental cues or cellular stress signals. These signals activate Bcl-2 homology 3 (BH3) 3The abbreviations used are: BH3Bcl-2 homology 3BIRbaculoviral IAP-repeatCHAPS3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acidDR5death receptor 5FasLFas ligandIAPinhibitor of apoptosisXIAPX chromosome-linked IAPPARAproapoptotic receptor agonistsiRNAsmall interfering RNASMACsecond mitochondrial activator of caspasesTNFtumor necrosis factorTNFRTNF receptor. proteins, leading to neutralization of the antiapoptotic proteins, such as Bcl-2, Bcl-xL, or Mcl-1, activation of proapoptotic proteins Bax and Bak, and subsequent disruption of mitochondrial membrane potential (7.Cory S. Adams J.M. Nat. Rev. Cancer. 2002; 2: 647-656Crossref PubMed Scopus (3291) Google Scholar). The resulting release of cytochrome c from the mitochondria into the cytoplasm leads to Apaf-1-mediated caspase-9 activation and consequent activation of effector caspases-3 and -7 and culminates in cell death.The extrinsic apoptotic pathway is triggered when proapoptotic receptors such as Fas or death receptor 5 (DR5) are engaged by their respective ligands, resulting in recruitment of the adaptor protein FADD and the apical caspases 8- or -10 (3.Ashkenazi A. Dixit V.M. Science. 1998; 281: 1305-1308Crossref PubMed Scopus (5114) Google Scholar). Incorporation of these caspases into the receptor-associated death-inducing signaling complex causes their autoactivation and leads to ensuing activation of effector caspases-3 and -7. In most cell types (type II cells), amplification of extrinsic pathway signaling through caspase-8-mediated activation of the BH3-only protein Bid is critical for efficient execution of apoptosis (8.Strasser A. Jost P.J. Nagata S. Immunity. 2009; 30: 180-192Abstract Full Text Full Text PDF PubMed Scopus (665) Google Scholar, 9.Walter D. Schmich K. Vogel S. Pick R. Kaufmann T. Hochmuth F.C. Haber A. Neubert K. McNelly S. von Weizsäcker F. Merfort I. Maurer U. Strasser A. Borner C. Hepatology. 2008; 48: 1942-1953Crossref PubMed Scopus (49) Google Scholar); in type I cells direct activation of effector caspases by caspase-8 is sufficient. Bid plays an important role in a number of cellular pathways including regulation of Fas- and TNFR1-mediated hepatocellular injury (9.Walter D. Schmich K. Vogel S. Pick R. Kaufmann T. Hochmuth F.C. Haber A. Neubert K. McNelly S. von Weizsäcker F. Merfort I. Maurer U. Strasser A. Borner C. Hepatology. 2008; 48: 1942-1953Crossref PubMed Scopus (49) Google Scholar, 10.Kaufmann T. Jost P.J. Pellegrini M. Puthalakath H. Gugasyan R. Gerondakis S. Cretney E. Smyth M.J. Silke J. Hakem R. Bouillet P. Mak T.W. Dixit V.M. Strasser A. Immunity. 2009; 30: 56-66Abstract Full Text Full Text PDF PubMed Scopus (109) Google Scholar, 11.Kaufmann T. Tai L. Ekert P.G. Huang D.C. Norris F. Lindemann R.K. Johnstone R.W. Dixit V.M. Strasser A. Cell. 2007; 129: 423-433Abstract Full Text Full Text PDF PubMed Scopus (168) Google Scholar, 12.Yin X.M. Wang K. Gross A. Zhao Y. Zinkel S. Klocke B. Roth K.A. Korsmeyer S.J. Nature. 1999; 400: 886-891Crossref PubMed Scopus (860) Google Scholar, 13.Zinkel S.S. Hurov K.E. Ong C. Abtahi F.M. Gross A. Korsmeyer S.J. Cell. 2005; 122: 579-591Abstract Full Text Full Text PDF PubMed Scopus (196) Google Scholar). In addition to stimulation by their respective ligands, proapoptotic receptors can be engaged by agonistic antibodies (14.Ashkenazi A. Cytokine Growth Factor Rev. 2008; 19: 325-331Crossref PubMed Scopus (327) Google Scholar). DR5 agonist antibody (PRO95780) binds DR5 tightly and selectively, triggering apoptosis in various types of cancer cells and inhibiting tumor xenograft growth in vivo (15.Adams C. Totpal K. Lawrence D. Marsters S. Pitti R. Yee S. Ross S. Deforge L. Koeppen H. Sagolla M. Compaan D. Lowman H. Hymowitz S. Ashkenazi A. Cell Death Differ. 2008; 15: 751-761Crossref PubMed Scopus (121) Google Scholar, 16.Jin H. Yang R. Ross J. Fong S. Carano R. Totpal K. Lawrence D. Zheng Z. Koeppen H. Stern H. Schwall R. Ashkenazi A. Clin. Cancer Res. 2008; 14: 7733-7740Crossref PubMed Scopus (50) Google Scholar).IAP proteins represent the ultimate line of defense against cellular suicide by regulating caspase activity and preventing caspase activation (17.Salvesen G.S. Duckett C.S. Nat. Rev. Mol. Cell Biol. 2002; 3: 401-410Crossref PubMed Scopus (1566) Google Scholar). c-IAP1 and c-IAP2 are components of TNF receptor (TNFR) complexes where they modulate apoptotic signaling and caspase-8 activation (18.Rothe M. Pan M.G. Henzel W.J. Ayres T.M. Goeddel D.V. Cell. 1995; 83: 1243-1252Abstract Full Text PDF PubMed Scopus (1050) Google Scholar, 19.Wang C.Y. Mayo M.W. Korneluk R.G. Goeddel D.V. Baldwin Jr., A.S. Science. 1998; 281: 1680-1683Crossref PubMed Scopus (2563) Google Scholar, 20.Bertrand M.J. Milutinovic S. Dickson K.M. Ho W.C. Boudreault A. Durkin J. Gillard J.W. Jaquith J.B. Morris S.J. Barker P.A. Mol. Cell. 2008; 30: 689-700Abstract Full Text Full Text PDF PubMed Scopus (829) Google Scholar). X chromosome-linked IAP (XIAP) is the only true endogenous inhibitor of caspases because other IAP proteins exhibit weak binding to and inhibition of caspases (21.Eckelman B.P. Salvesen G.S. Scott F.L. EMBO Rep. 2006; 7: 988-994Crossref PubMed Scopus (657) Google Scholar). XIAP inhibits caspases-3 and -7 using the linker region between its baculoviral IAP-repeat (BIR) domain 1 (BIR1) and BIR2 as well as the BIR2 domain, whereas inhibition of caspase-9 relies on the binding of the BIR3 domain to an N-terminal IAP-binding motif of partially processed caspase-9 (21.Eckelman B.P. Salvesen G.S. Scott F.L. EMBO Rep. 2006; 7: 988-994Crossref PubMed Scopus (657) Google Scholar, 22.Shiozaki E.N. Chai J. Rigotti D.J. Riedl S.J. Li P. Srinivasula S.M. Alnemri E.S. Fairman R. Shi Y. Mol. Cell. 2003; 11: 519-527Abstract Full Text Full Text PDF PubMed Scopus (565) Google Scholar). Caspase inhibition by XIAP is blocked by second mitochondrial activator of caspases (SMAC) (23.Du C. Fang M. Li Y. Li L. Wang X. Cell. 2000; 102: 33-42Abstract Full Text Full Text PDF PubMed Scopus (2891) Google Scholar, 24.Verhagen A.M. Ekert P.G. Pakusch M. Silke J. Connolly L.M. Reid G.E. Moritz R.L. Simpson R.J. Vaux D.L. Cell. 2000; 102: 43-53Abstract Full Text Full Text PDF PubMed Scopus (1962) Google Scholar). During induction of apoptosis, SMAC undergoes proteolyic processing, resulting in its release from mitochondria into the cytoplasm where it can bind to and antagonize the BIR2 and BIR3 domains of XIAP via an exposed IAP-binding motif (23.Du C. Fang M. Li Y. Li L. Wang X. Cell. 2000; 102: 33-42Abstract Full Text Full Text PDF PubMed Scopus (2891) Google Scholar, 24.Verhagen A.M. Ekert P.G. Pakusch M. Silke J. Connolly L.M. Reid G.E. Moritz R.L. Simpson R.J. Vaux D.L. Cell. 2000; 102: 43-53Abstract Full Text Full Text PDF PubMed Scopus (1962) Google Scholar). IAP-mediated inhibition of cell death and promotion of survival signaling pathways are important for tumor maintenance and therapeutic resistance to anticancer agents. These properties distinguish IAP proteins as attractive targets for anticancer therapeutic intervention (25.Vucic D. Fairbrother W.J. Clin. Cancer Res. 2007; 13: 5995-6000Crossref PubMed Scopus (169) Google Scholar). Efforts to identify small molecule antagonists of IAPs have led to the discovery of a number of IAP antagonistic compounds that possess antiapoptotic activity both in vitro and in vivo (26.Flygare J.A. Vucic D. Future Oncol. 2009; 5: 141-144Crossref PubMed Scopus (6) Google Scholar, 27.LaCasse E.C. Mahoney D.J. Cheung H.H. Plenchette S. Baird S. Korneluk R.G. Oncogene. 2008; 27: 6252-6275Crossref PubMed Scopus (417) Google Scholar). These IAP antagonists induce cell death that depends on TNF signaling, stimulation of NF-κB pathways, and caspase activation (28.Gaither A. Porter D. Yao Y. Borawski J. Yang G. Donovan J. D. J. M. C. T. Huang A. Y. R. M. S. L. Cancer Res. 2007; PubMed Scopus Google Scholar, Wang L. A. Li L. M. J. P. Wang X. Cancer Cell. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar, E. J.W. S.M. P. K. J.A. Fairbrother W.J. K. Dixit V.M. Vucic D. Cell. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar, R. D. S.M. M. R. M. P. F. Vaux D.L. Silke J. Cell. 2007; Full Text Full Text PDF PubMed Scopus Google we demonstrate that combination of IAP antagonists and proapoptotic receptor agonists Fas ligand (FasL) or DR5 agonist synergistically apoptosis in cancer cells and inhibits tumor growth in to its role in IAP cell death, is not for synergistic activity of and IAP In type II cells, or DR5 agonist apoptosis is efficiently inhibited by of Bid. However, of XIAP or antagonism of XIAP by small rescues the effect of Bid knockdown in these cells by activation of effector caspases via a type thus efficient These a for of IAP antagonists and proapoptotic receptor agonists as a cancer therapeutic to of the apoptotic pathways into cancer have that are IAP proteins are at in tumor types A.M. E.C. Korneluk R.G. 2007; PubMed Scopus Google Scholar). In IAP-mediated inhibition of cell death and promotion of survival signaling pathways distinguish IAP proteins as attractive targets for anticancer therapeutic intervention (26.Flygare J.A. Vucic D. Future Oncol. 2009; 5: 141-144Crossref PubMed Scopus (6) Google Scholar). is on engagement of the proapoptotic receptors DR5 A. Nat. Rev. 2008; 7: PubMed Scopus Google Scholar). and DR5 to be in tumor and the DR5 agonist antibody activity in vitro and in vivo and is (15.Adams C. Totpal K. Lawrence D. Marsters S. Pitti R. Yee S. Ross S. Deforge L. Koeppen H. Sagolla M. Compaan D. Lowman H. Hymowitz S. Ashkenazi A. Cell Death Differ. 2008; 15: 751-761Crossref PubMed Scopus (121) Google Scholar, 16.Jin H. Yang R. Ross J. Fong S. Carano R. Totpal K. Lawrence D. Zheng Z. Koeppen H. Stern H. Schwall R. Ashkenazi A. Clin. Cancer Res. 2008; 14: 7733-7740Crossref PubMed Scopus (50) Google Scholar, A. Nat. Rev. 2008; 7: PubMed Scopus Google Scholar). of these anticancer proapoptotic thus potential therapeutic S. M. K.M. Nat. 2002; PubMed Scopus Google Scholar, M. H. D. F. M. U. C. P. T. K.M. S. Cancer Res. 2009; PubMed Scopus Google Scholar). However, the of the synergistic between IAP antagonists and In the we have critical of tumor combination that to of proapoptotic receptor signaling and its regulation by IAP antagonists induce caspase-8 activation and cell death in a of cancer cell in a (28.Gaither A. Porter D. Yao Y. Borawski J. Yang G. Donovan J. D. J. M. C. T. Huang A. Y. R. M. S. L. Cancer Res. 2007; PubMed Scopus Google Scholar, Wang L. A. Li L. M. J. P. Wang X. Cancer Cell. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar, E. J.W. S.M. P. K. J.A. Fairbrother W.J. K. Dixit V.M. Vucic D. Cell. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar, R. D. S.M. M. R. M. P. F. Vaux D.L. Silke J. Cell. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar). process of The that combination of IAP antagonists and synergistically cause apoptosis of signaling or protein In we that IAP antagonists not caspase-8 activation by FasL or DR5 agonist they and caspase-9 activation by these the synergistic activity of inhibition of the and a of XIAP protein and DR5 agonist and other proapoptotic are important in regulating development and homeostasis and have critical roles in (8.Strasser A. Jost P.J. Nagata S. Immunity. 2009; 30: 180-192Abstract Full Text Full Text PDF PubMed Scopus (665) Google Scholar). These receptors apoptosis by caspase-8 through the of the death-inducing signaling In cells (type I cells), apoptotic signal for efficient activation of the effector caspases-3 and without the need for XIAP resulting in cell However, in most cell (type II cells), signal to be to amplification of the release of cytochrome c and endogenous XIAP such as from the a for XIAP antagonism as a of death apoptotic signaling. XIAP the apoptosis between cell types is not its be of The of XIAP that block caspase-8-mediated effector caspase activation on the of caspase-8 activation as well as the of the between caspase activation and the of XIAP to inhibit caspase activity between cell of XIAP through of its or by small molecule IAP antagonists the need for mitochondrial amplification of the apoptotic signal by activation of the effector caspases, resulting in efficient death in cancer cell that are to or DR5 agonist the a for the synergistic combination of IAP antagonists and FasL or DR5 agonist antibody and that inhibition of the effector caspases is an important of proapoptotic Jost P.J. S. D. U. Huang D.C. Bouillet P. Borner C. Silke J. Strasser A. Kaufmann T. Nature. 2009; PubMed Scopus Google a on the role of XIAP in apoptotic signaling. Jost P.J. S. D. U. Huang D.C. Bouillet P. Borner C. Silke J. Strasser A. Kaufmann T. Nature. 2009; PubMed Scopus Google used and to demonstrate that XIAP is a critical between type I and type II apoptotic signaling. the Jost by for the of XIAP in and DR5 agonist apoptosis in cancer cells and by that signaling does not a role in these apoptotic IntroductionApoptosis, or programmed cell death, is a genetically regulated process with critical roles in development and homeostasis in metazoans (1.Steller H. Science. 1995; 267: 1445-1449Crossref PubMed Scopus (2423) Google Scholar). Deficient apoptosis leads to the absence of normal cell death and contributes to the development and progression of human cancers (2.Fesik S.W. Nat. Rev. Cancer. 2005; 5: 876-885Crossref PubMed Scopus (926) Google Scholar). Apoptotic cell death can be initiated through the engagement of cell surface proapoptotic receptors by their specific ligands or by changes in internal cellular integrity (3.Ashkenazi A. Dixit V.M. Science. 1998; 281: 1305-1308Crossref PubMed Scopus (5114) Google Scholar, 4.Kaufmann S.H. Vaux D.L. Oncogene. 2003; 22: 7414-7430Crossref PubMed Scopus (254) Google Scholar). Both of these pathways converge at the activation of caspases, cysteine-dependent aspartyl-specific proteases that comprise the effector arm of apoptotic cell death (5.Salvesen G.S. Abrams J.M. Oncogene. 2004; 23: 2774-2784Crossref PubMed Scopus (212) Google Scholar, 6.Shi Y. Protein Sci. 2004; 13: 1979-1987Crossref PubMed Scopus (244) Google Scholar). The intrinsic or mitochondrial pathway is initiated by developmental cues or cellular stress signals. These signals activate Bcl-2 homology 3 (BH3) 3The abbreviations used are: BH3Bcl-2 homology 3BIRbaculoviral IAP-repeatCHAPS3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acidDR5death receptor 5FasLFas ligandIAPinhibitor of apoptosisXIAPX chromosome-linked IAPPARAproapoptotic receptor agonistsiRNAsmall interfering RNASMACsecond mitochondrial activator of caspasesTNFtumor necrosis factorTNFRTNF receptor. proteins, leading to neutralization of the antiapoptotic proteins, such as Bcl-2, Bcl-xL, or Mcl-1, activation of proapoptotic proteins Bax and Bak, and subsequent disruption of mitochondrial membrane potential (7.Cory S. Adams J.M. Nat. Rev. Cancer. 2002; 2: 647-656Crossref PubMed Scopus (3291) Google Scholar). The resulting release of cytochrome c from the mitochondria into the cytoplasm leads to Apaf-1-mediated caspase-9 activation and consequent activation of effector caspases-3 and -7 and culminates in cell death.The extrinsic apoptotic pathway is triggered when proapoptotic receptors such as Fas or death receptor 5 (DR5) are engaged by their respective ligands, resulting in recruitment of the adaptor protein FADD and the apical caspases 8- or -10 (3.Ashkenazi A. Dixit V.M. Science. 1998; 281: 1305-1308Crossref PubMed Scopus (5114) Google Scholar). Incorporation of these caspases into the receptor-associated death-inducing signaling complex causes their autoactivation and leads to ensuing activation of effector caspases-3 and -7. In most cell types (type II cells), amplification of extrinsic pathway signaling through caspase-8-mediated activation of the BH3-only protein Bid is critical for efficient execution of apoptosis (8.Strasser A. Jost P.J. Nagata S. Immunity. 2009; 30: 180-192Abstract Full Text Full Text PDF PubMed Scopus (665) Google Scholar, 9.Walter D. Schmich K. Vogel S. Pick R. Kaufmann T. Hochmuth F.C. Haber A. Neubert K. McNelly S. von Weizsäcker F. Merfort I. Maurer U. Strasser A. Borner C. Hepatology. 2008; 48: 1942-1953Crossref PubMed Scopus (49) Google Scholar); in type I cells direct activation of effector caspases by caspase-8 is sufficient. Bid plays an important role in a number of cellular pathways including regulation of Fas- and TNFR1-mediated hepatocellular injury (9.Walter D. Schmich K. Vogel S. Pick R. Kaufmann T. Hochmuth F.C. Haber A. Neubert K. McNelly S. von Weizsäcker F. Merfort I. Maurer U. Strasser A. Borner C. Hepatology. 2008; 48: 1942-1953Crossref PubMed Scopus (49) Google Scholar, 10.Kaufmann T. Jost P.J. Pellegrini M. Puthalakath H. Gugasyan R. Gerondakis S. Cretney E. Smyth M.J. Silke J. Hakem R. Bouillet P. Mak T.W. Dixit V.M. Strasser A. Immunity. 2009; 30: 56-66Abstract Full Text Full Text PDF PubMed Scopus (109) Google Scholar, 11.Kaufmann T. Tai L. Ekert P.G. Huang D.C. Norris F. Lindemann R.K. Johnstone R.W. Dixit V.M. Strasser A. Cell. 2007; 129: 423-433Abstract Full Text Full Text PDF PubMed Scopus (168) Google Scholar, 12.Yin X.M. Wang K. Gross A. Zhao Y. Zinkel S. Klocke B. Roth K.A. Korsmeyer S.J. Nature. 1999; 400: 886-891Crossref PubMed Scopus (860) Google Scholar, 13.Zinkel S.S. Hurov K.E. Ong C. Abtahi F.M. Gross A. Korsmeyer S.J. Cell. 2005; 122: 579-591Abstract Full Text Full Text PDF PubMed Scopus (196) Google Scholar). In addition to stimulation by their respective ligands, proapoptotic receptors can be engaged by agonistic antibodies (14.Ashkenazi A. Cytokine Growth Factor Rev. 2008; 19: 325-331Crossref PubMed Scopus (327) Google Scholar). DR5 agonist antibody (PRO95780) binds DR5 tightly and selectively, triggering apoptosis in various types of cancer cells and inhibiting tumor xenograft growth in vivo (15.Adams C. Totpal K. Lawrence D. Marsters S. Pitti R. Yee S. Ross S. Deforge L. Koeppen H. Sagolla M. Compaan D. Lowman H. Hymowitz S. Ashkenazi A. Cell Death Differ. 2008; 15: 751-761Crossref PubMed Scopus (121) Google Scholar, 16.Jin H. Yang R. Ross J. Fong S. Carano R. Totpal K. Lawrence D. Zheng Z. Koeppen H. Stern H. Schwall R. Ashkenazi A. Clin. Cancer Res. 2008; 14: 7733-7740Crossref PubMed Scopus (50) Google Scholar).IAP proteins represent the ultimate line of defense against cellular suicide by regulating caspase activity and preventing caspase activation (17.Salvesen G.S. Duckett C.S. Nat. Rev. Mol. Cell Biol. 2002; 3: 401-410Crossref PubMed Scopus (1566) Google Scholar). c-IAP1 and c-IAP2 are components of TNF receptor (TNFR) complexes where they modulate apoptotic signaling and caspase-8 activation (18.Rothe M. Pan M.G. Henzel W.J. Ayres T.M. Goeddel D.V. Cell. 1995; 83: 1243-1252Abstract Full Text PDF PubMed Scopus (1050) Google Scholar, 19.Wang C.Y. Mayo M.W. Korneluk R.G. Goeddel D.V. Baldwin Jr., A.S. Science. 1998; 281: 1680-1683Crossref PubMed Scopus (2563) Google Scholar, 20.Bertrand M.J. Milutinovic S. Dickson K.M. Ho W.C. Boudreault A. Durkin J. Gillard J.W. Jaquith J.B. Morris S.J. Barker P.A. Mol. Cell. 2008; 30: 689-700Abstract Full Text Full Text PDF PubMed Scopus (829) Google Scholar). X chromosome-linked IAP (XIAP) is the only true endogenous inhibitor of caspases because other IAP proteins exhibit weak binding to and inhibition of caspases (21.Eckelman B.P. Salvesen G.S. Scott F.L. EMBO Rep. 2006; 7: 988-994Crossref PubMed Scopus (657) Google Scholar). XIAP inhibits caspases-3 and -7 using the linker region between its baculoviral IAP-repeat (BIR) domain 1 (BIR1) and BIR2 as well as the BIR2 domain, whereas inhibition of caspase-9 relies on the binding of the BIR3 domain to an N-terminal IAP-binding motif of partially processed caspase-9 (21.Eckelman B.P. Salvesen G.S. Scott F.L. EMBO Rep. 2006; 7: 988-994Crossref PubMed Scopus (657) Google Scholar, 22.Shiozaki E.N. Chai J. Rigotti D.J. Riedl S.J. Li P. Srinivasula S.M. Alnemri E.S. Fairman R. Shi Y. Mol. Cell. 2003; 11: 519-527Abstract Full Text Full Text PDF PubMed Scopus (565) Google Scholar). Caspase inhibition by XIAP is blocked by second mitochondrial activator of caspases (SMAC) (23.Du C. Fang M. Li Y. Li L. Wang X. Cell. 2000; 102: 33-42Abstract Full Text Full Text PDF PubMed Scopus (2891) Google Scholar, 24.Verhagen A.M. Ekert P.G. Pakusch M. Silke J. Connolly L.M. Reid G.E. Moritz R.L. Simpson R.J. Vaux D.L. Cell. 2000; 102: 43-53Abstract Full Text Full Text PDF PubMed Scopus (1962) Google Scholar). During induction of apoptosis, SMAC undergoes proteolyic processing, resulting in its release from mitochondria into the cytoplasm where it can bind to and antagonize the BIR2 and BIR3 domains of XIAP via an exposed IAP-binding motif (23.Du C. Fang M. Li Y. Li L. Wang X. Cell. 2000; 102: 33-42Abstract Full Text Full Text PDF PubMed Scopus (2891) Google Scholar, 24.Verhagen A.M. Ekert P.G. Pakusch M. Silke J. Connolly L.M. Reid G.E. Moritz R.L. Simpson R.J. Vaux D.L. Cell. 2000; 102: 43-53Abstract Full Text Full Text PDF PubMed Scopus (1962) Google Scholar). IAP-mediated inhibition of cell death and promotion of survival signaling pathways are important for tumor maintenance and therapeutic resistance to anticancer agents. These properties distinguish IAP proteins as attractive targets for anticancer therapeutic intervention (25.Vucic D. Fairbrother W.J. Clin. Cancer Res. 2007; 13: 5995-6000Crossref PubMed Scopus (169) Google Scholar). Efforts to identify small molecule antagonists of IAPs have led to the discovery of a number of IAP antagonistic compounds that possess antiapoptotic activity both in vitro and in vivo (26.Flygare J.A. Vucic D. Future Oncol. 2009; 5: 141-144Crossref PubMed Scopus (6) Google Scholar, 27.LaCasse E.C. Mahoney D.J. Cheung H.H. Plenchette S. Baird S. Korneluk R.G. Oncogene. 2008; 27: 6252-6275Crossref PubMed Scopus (417) Google Scholar). These IAP antagonists induce cell death that depends on TNF signaling, stimulation of NF-κB pathways, and caspase activation (28.Gaither A. Porter D. Yao Y. Borawski J. Yang G. Donovan J. D. J. M. C. T. Huang A. Y. R. M. S. L. Cancer Res. 2007; PubMed Scopus Google Scholar, Wang L. A. Li L. M. J. P. Wang X. Cancer Cell. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar, E. J.W. S.M. P. K. J.A. Fairbrother W.J. K. Dixit V.M. Vucic D. Cell. 2007; Full Text Full Text PDF PubMed Scopus Google Scholar, R. D. S.M. M. R. M. P. F. Vaux D.L. Silke J. Cell. 2007; Full Text Full Text PDF PubMed Scopus Google we demonstrate that combination of IAP antagonists and proapoptotic receptor agonists Fas ligand (FasL) or DR5 agonist synergistically apoptosis in cancer cells and inhibits tumor growth in to its role in IAP cell death, is not for synergistic activity of and IAP In type II cells, or DR5 agonist apoptosis is efficiently inhibited by of Bid. However, of XIAP or antagonism of XIAP by small rescues the effect of Bid knockdown in these cells by activation of effector caspases via a type thus efficient These a for of IAP antagonists and proapoptotic receptor agonists as a cancer therapeutic
25